

Date: 26th July, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
BSE Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: Successful completion of USFDA inspection at Alembic Pharmaceuticals Limited' Oral Solid Formulation Facility (F-I) at Panelav

We would like to inform the exchange that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oral Solid Formulation Facility (F-I) located at Panelav. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from 17th July, 2024 to 26th July, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED